Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 0.1723 USD -1.49% Market Closed
Market Cap: 11.3m USD
Have any thoughts about
Lyra Therapeutics Inc?
Write Note

Lyra Therapeutics Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lyra Therapeutics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Lyra Therapeutics Inc
NASDAQ:LYRA
Stock-Based Compensation
$5.9m
CAGR 3-Years
48%
CAGR 5-Years
70%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Stock-Based Compensation
$698m
CAGR 3-Years
-11%
CAGR 5-Years
0%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Stock-Based Compensation
$741m
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
10%
Eli Lilly and Co
NYSE:LLY
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lyra Therapeutics Inc
Glance View

Market Cap
11.3m USD
Industry
Pharmaceuticals

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

LYRA Intrinsic Value
0.4011 USD
Undervaluation 57%
Intrinsic Value
Price

See Also

What is Lyra Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
5.9m USD

Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Stock-Based Compensation amounts to 5.9m USD.

What is Lyra Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
70%

Over the last year, the Stock-Based Compensation growth was 8%. The average annual Stock-Based Compensation growth rates for Lyra Therapeutics Inc have been 48% over the past three years , 70% over the past five years .

Back to Top